After seven months of continuing resolutions, Congress voted to pass a $1.1 trillion spending bill covering the remainder of the fiscal year 2017—approving a $2 billion increase for NIH.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
